Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Health Products Guidance: Not Just For Dietary Supplements Anymore

Executive Summary

The FTC has updated its guidance on health products advertising for the first time in 25 years with an expanded version that includes devices.

You may also be interested in...



Companies Targeted By FTC Using Penalty Offense Authority Have Strong Defense, Attorney Says

John Villafranco, partner at Kelly Drye & Warren LLP, says the US FTC’s ability to obtain monetary relief using the penalty offense mechanism is questionable both on statutory and Constitutional grounds. Marketers faced with civil penalties – for example, for alleged inadequately substantiated health claims – should stand their ground, he suggests in a recent interview.

Expert: FTC Clinical Data Requirements A Likely Challenge For Medtech Companies

Medtech Insight spoke to Sidley Austin LLP partner Jeff Senger about the challenges companies may face navigating the FTC’s updated health products guidance.

Digital Health Briefs: Digital Health Funding Hits New High; FTC Mobile Apps Focus

Rock Health’s Q3 update shows that funding for digital health so far in 2013 has already outpaced 2012 full-year levels. FTC emphasizes interest in mobile app claims. Some Senators want HHS to delay stage 2 of the electronic medical records meaningful use requirements. More digital health news.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel